RxDoctor Payments DataLook up a doctor →

Amer Rassam, MD

Hematology-Oncology · Tallahassee, FLNPI 1952370769

Payments from drug & device makers

$10,982in general payments, 2019–2025

Across 247 payments — averaging $44.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Onmark, Inc.$4K
  • US Oncology Corporate, Inc.$2K
  • Novartis$715
  • Pfizer$397
  • Merck$354
  • Astellas Pharma US Inc$334
  • plus $4K from 44 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Onmark, Inc.10$3,999
US Oncology Corporate, Inc.4$1,516
Novartis35$715
Pfizer20$397
Merck16$354
Astellas Pharma US Inc8$334
Bristol Myers Squibb13$308
Mckesson Specialty Care Distribution, LLC3$256
Eisai Inc.11$217
Sanofi8$195
Lilly USA, LLC9$168
AstraZeneca(2 entities)8$163
Incyte Corporation4$160
Johnson & Johnson8$158
Takeda Pharmaceuticals U.S.A., Inc.3$147
E.r. Squibb & Sons, L.L.C.7$145
Seagen Inc.3$135
Coherus Oncology, Inc.7$134
Exelixis Inc.6$130
Amgen5$109
GSK5$106
Sanofi-aventis U.S. LLC1$100
Boehringer Ingelheim4$98
Octapharma USA, Inc.5$93
Regeneron Healthcare Solutions, Inc.5$85
Janssen Scientific Affairs, LLC3$72
Genentech USA, Inc.3$65
Daiichi Sankyo Inc.3$64
Gilead3$51
Novocure Inc.3$46
Tempus AI, Inc2$41
Pharmacosmos Therapeutics Inc.2$30
Jazz Pharmaceuticals Inc.1$29
Teva Pharmaceuticals USA, Inc.2$29
CSL Behring1$26
Stemline Therapeutics Inc.1$26
Array Biopharma Inc1$25
Puma Biotechnology, Inc.1$24
Kyowa Kirin, Inc.1$23
Fennec Pharmaceuticals, Inc.1$23
Caris MPI, Inc.1$22
Myriad Genetic Laboratories, Inc.1$22
Servier Pharmaceuticals LLC1$21
EMD Serono, Inc.1$20
Beone Medicines USA, Inc.1$19
Rigel Pharmaceuticals, Inc.2$19
Taiho Oncology, Inc.1$17
G1 Therapeutics, Inc.1$17
Karyopharm Therapeutics Inc.1$15
Helsinn Therapeutics (U.S.), Inc.1$15

How this compares

Too few hematology-oncology providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$662,630
Medicare patients
148
Services billed
36,866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology-oncology in Tallahassee

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →